Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Results and Performance
IBRX logo

ImmunityBio Achieves 168% Revenue Surge Following ANKTIVA Commercialization

IBRX10-QFiling Date: 5/7/2026
ImmunityBio, Inc.
Description

What this story covers

ImmunityBio reports 168% revenue growth to $44.2 million from ANKTIVA sales, despite a $632.8 million net loss due to non-cash items. The company holds $380.9 million in liquidity, managing significant debt and ongoing legal issues.

Story snapshot

CompanyImmunityBio, Inc.
TickerIBRX
VariantStandard detailed
Duration11:41
Filing type10-Q
PeriodQ4 2026
IndustryHealthcare & Pharmaceuticals
Accession0001326110-26-000059
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in